892
Views
12
CrossRef citations to date
0
Altmetric
Review

New drugs under development for COPD

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 419-431 | Received 20 Jul 2020, Accepted 02 Sep 2020, Published online: 29 Sep 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Maria Gabriella Matera, Luigino Calzetta, Rosa Annibale, Francesco Russo & Mario Cazzola. (2021) Classes of drugs that target the cellular components of inflammation under clinical development for COPD. Expert Review of Clinical Pharmacology 14:8, pages 1015-1027.
Read now

Articles from other publishers (11)

Lucas Pires Guarnier, Lincoln Gozzi Moro, Francislaine Aparecida dos Reis Lívero, Carolina Arruda de Faria, Mauricio Fogaça Azevedo, Beatriz Pizoni Roma, Edilson Rodrigues Albuquerque, Maria José Malagutti-Ferreira, Alessandra Gomes Duarte Rodrigues, Adelson Alves da Silva, Eliseo Joji Sekiya & João Tadeu Ribeiro-Paes. (2023) Regenerative and translational medicine in COPD: hype and hope. European Respiratory Review 32:169, pages 220223.
Crossref
Austin Heffernan, Amir Shafiee, Teffran Chan, Sydney Sparanese & Andrew Thamboo. (2023) Non‐Type 2 and Mixed Inflammation in Chronic Rhinosinusitis and Lower Airway Disease. The Laryngoscope.
Crossref
Jacek Plichta, Piotr Kuna & Michał Panek. (2023) Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives. Frontiers in Immunology 14.
Crossref
Gang Li, Dengqin He, Xiaojia Cai, Wen Guan, Yali Zhang, Jia-Qiang Wu & Hongliang Yao. (2023) Advances in the development of phosphodiesterase-4 inhibitors. European Journal of Medicinal Chemistry 250, pages 115195.
Crossref
Sharon Mumby & Ian M Adcock. (2022) Recent evidence from omic analysis for redox signalling and mitochondrial oxidative stress in COPD. Journal of Inflammation 19:1.
Crossref
Isabel UWAGBOE, Ian M. ADCOCK, Federica LO BELLO, Gaetano CARAMORI & Sharon MUMBY. (2022) New drugs under development for COPD. Minerva Medica 113:3.
Crossref
Luigino Calzetta, Marina Aiello, Annalisa Frizzelli, Francesca Camardelli, Mario Cazzola, Paola Rogliani & Alfredo Chetta. (2022) Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis. Cells 11:11, pages 1797.
Crossref
Annalisa Bianchera, Esraa Alomari & Stefano Bruno. (2022) Augmentation Therapy with Alpha-1 Antitrypsin: Present and Future of Production, Formulation, and Delivery. Current Medicinal Chemistry 29:3, pages 385-410.
Crossref
Natália Pereira da Silva Araújo, Natália Alves de Matos, Michel Oliveira, Ana Beatriz Farias de Souza, Thalles de Freitas Castro, Pedro Alves Machado-Júnior, Débora Maria Soares de Souza, André Talvani, Sílvia Dantas Cangussú, Rodrigo Cunha Alvim de Menezes & Frank Silva Bezerra. (2022) Quercetin Improves Pulmonary Function and Prevents Emphysema Caused by Exposure to Cigarette Smoke in Male Mice. Antioxidants 11:2, pages 181.
Crossref
Mario Cazzola & Maria Gabriella Matera. (2021) Is it time to look beyond bronchodilators and corticosteroids in treating COPD?. Future Drug Discovery 3:2.
Crossref
Alberto Papi, Bianca Beghé & Leonardo M. Fabbri. (2021) Rate of Decline of FEV 1 as a Biomarker of Survival? . American Journal of Respiratory and Critical Care Medicine 203:6, pages 663-665.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.